Citations

Clear

1526 citation(s) found for "Sun, Yu".

The economic impact associated with stent retriever selection for the treatment of acute ischemic stroke: a cost–effectiveness analysis of MASTRO I data from a Chinese healthcare system perspective
Zaidat, Osama O. , Yang, Xinguang , Brinjikji, Waleed , Kottenmeier, Emilie , Maheswaran, Hendramoorthy , Galvain, Thibaut , Brouwer, Patrick A. , Mirza, Mahmood , Andersson, Tommy , Andersson, Tommy , Brouwer, Patrick , Kottenmeier, Emilie

Mayo Clinic

Journal of Comparative Effectiveness Research | November 5, 2024 | Volume: 13 | Issue: 11 | Pages: No page available

10.57264/cer-2024-0160 | PMID 39498634 Get It

Aim: The aim of this analysis was to assess the cost–effectiveness of the EmboTrap ® Revascularization Device compared with the Solitaire™ Revascularization Device and Trevo ® Retriever for the treatment of acute ischemic stroke (AIS) from the perspective of the Chinese healthcare system. Methods: According to MASTRO I, a recent living systematic literature review and meta-analysis, mechanical thrombectomy (MT) with EmboTrap in the treatment of AIS resulted in better functional outcomes compared with the use of Solitaire or Trevo. Based on the proportion of patients that achieved 90-day modified Rankin Scale (mRS) scores of 0–2, 3–5 and 6 reported in MASTRO I, a combined 90-day short-term decision tree and Markov model with a 10-year time horizon was used to compare the cost–effectiveness of the three devices. The primary outcome was the incremental cost–effectiveness ratio (ICER), representing the incremental cost (in 2022 Chinese Yuan [CNY]) per incremental quality-adjusted life-year (QALY). The ICERs were compared against willingness-to-pay (WTP) thresholds of 1, 1.5 and 3-times the 2022 national gross domestic product (GDP) per capita in China. Results: Treatment with EmboTrap resulted in total QALYs of 3.28 and total costs of 110,058 CNY per patient. Treatment with Trevo resulted in total QALYs of 3.05 and total costs of 116,941 CNY per patient. Treatment with Solitaire resulted in total QALYs of 2.81 and total costs of 99,090 CNY per patient. Trevo was dominated by EmboTrap as it was a more costly and less effective intervention. As such, Trevo was not cost-effective at any WTP threshold. Compared with Solitaire, EmboTrap was more effective and more costly, with an ICER of 23,615 CNY per QALY. This result suggests that EmboTrap is cost-effective when compared with Solitaire since the ICER was lower than all WTP thresholds assessed. Conclusion: EmboTrap dominated Trevo and is cost-effective for the treatment of patients with AIS compared with Solitaire when assessed from the perspective of the Chinese healthcare system and based on the device-level meta-analysis MASTRO I. Selecting a stent retriever (SR) that optimizes 90-day mRS score is an important consideration from both a clinical and healthcare payer perspective in China as it is associated with reduced long-term costs and increased quality of life.
Predicting Post‐Mortem α‐Synuclein Pathology by the Combined Presence of Probable REM sleep behavior disorder and Hyposmia
Tremblay, Cécilia , Adler, Charles H. , Shill, Holly A. , Driver‐Dunckley, Erika, Mehta, Shyamal H. , Choudhury, Parichita , Belden, Christine M. , Lee‐Iannotti, Joyce , Beach, Thomas G. , Mehta, Shyamal, Beach, Thomas G , Adler, C H , Choudhury, Parichita , Driver‐Dunckley, Erika , Shprecher, David , Atri, Alireza , Serrano, Geidy E.

Mayo Clinic

Movement Disorders Clinical Practice | November 5, 2024 | Volume: 12 | Issue: 2 | Pages: 157-165

10.1002/mdc3.14244 | PMID 39499184 Get It

AbstractBackgroundIdiopathic rapid eye movement sleep behavior disorder (RBD) is a strong known predictor of a final clinicopathological diagnosis of a Lewy type α‐synucleinopathy (LTS). Olfactory dysfunction is an early symptom of synucleinopathies and has been repeatedly associated with the presence of post‐mortem LTS.ObjectiveTo assess the combined value of a clinician diagnosis of probable RBD (PRBD) and hyposmia in predicting the post‐mortem presence of LTS in a broader, less‐selected, volunteer elderly population.MethodsWe studied 652 autopsied subjects from the Arizona Study of Aging and Neurodegenerative Disorders, which were evaluated for PRBD, had completed annual movement and cognitive assessments, and had at least one the University of Pennsylvania Smell Identification Test (UPSIT) olfactory test.ResultsHistological evidence of LTS was significantly more frequent in those who had PRBD (112/152: 73.7%) than those without (177/494: 35.8%) (P < 0.001). LTS was more frequent in cases with PRBD and a low UPSIT score (90.8%) compared to cases with PRBD only (73.7%) (P < 0.001) or cases with a low UPSIT score only (69.4%) (P < 0.001). Sensitivity of PRBD diagnosis for predicting LTS was 38.8% and specificity 88.8%, whereas sensitivity of a low UPSIT score was 74.4% and specificity 73.4% (Youden's index = 0.276 for PRBD, 0.478 for UPSIT). When combining both measures, sensitivity was 34.3% and specificity increased to 97.2%.ConclusionPRBD, diagnosed without sleep study confirmation, combined with a reduced olfactory performance is highly specific for predicting post‐mortem presence of LTS. The combination of both measures may provide a cost‐effective means of predicting LTS in a broader community.
Non-canonical CDK6 activity promotes cilia disassembly by suppressing axoneme polyglutamylation
He, Kai , Sun, Xiaobo , Luc, San , Hao, Jielu , Zhang, Yingyi , Huang, Yan , Ji, Biyun , Ku, Pei-I , Subramanian, Radhika , Ling, Kun , Hu, Jinghua , Chen, Chuan , Luc, San , Robichaud, Jielu Hao , Zhang, Yingyi , Huang, Yan , Ji, Biyun , Ku, Pei-I , Subramanian, Radhika , Ling, Kun , Hu, Jinghua , He, Kai , Chen, Chuan

Mayo Clinic

Journal of Cell Biology | November 2, 2024 | Volume: 224 | Issue: 2 | Pages: No page available

10.1083/jcb.202405170 | PMID 39636239 Get It

Tubulin polyglutamylation is a posttranslational modification that occurs primarily along the axoneme of cilia. Defective axoneme polyglutamylation impairs cilia function and has been correlated with ciliopathies, including Joubert Syndrome (JBTS). However, the precise mechanisms regulating proper axoneme polyglutamylation remain vague. Here, we show that cyclin-dependent kinase 6 (CDK6), but not its paralog CDK4, localizes to the cilia base and suppresses axoneme polyglutamylation by phosphorylating RAB11 family interacting protein 5 (FIP5) at site S641, a critical regulator of cilia import of glutamylases. S641 phosphorylation disrupts the ciliary recruitment of FIP5 and its association with RAB11, thereby reducing the ciliary import of glutamylases. Encouragingly, the FDA-approved CDK4/6 inhibitor Abemaciclib can effectively restore cilia function in JBTS cells with defective glutamylation. In summary, our study elucidates the regulatory mechanisms governing axoneme polyglutamylation and suggests that developing CDK6-specific inhibitors could be a promising therapeutic strategy to enhance cilia function in ciliopathy patients.
Seizure Sources Can Be Imaged from Scalp EEG by Means of Biophysically Constrained Deep Neural Networks
Sun, Rui , Worrell, Gregory, He, Bin , He, Bin , Sohrabpour, Abbas , Joseph, Boney , Worrell, Gregory A.

Mayo Clinic

Advanced Science | October 30, 2024 | Volume: 11 | Issue: 47 | Pages: No page available

10.1002/advs.202405246 | PMID 39473085 Get It

Abstract Seizure localization is important for managing drug‐resistant focal epilepsy. Here, the capability of a novel deep learning‐based source imaging framework (DeepSIF) for imaging seizure activities from electroencephalogram (EEG) recordings in drug‐resistant focal epilepsy patients is investigated. The neural mass model of ictal oscillations is adopted to generate synthetic training data with spatio‐temporal‐spectra features similar to ictal dynamics. The trained DeepSIF model is rigorously validated using computer simulations and in a cohort of 33 drug‐resistant focal epilepsy patients with high‐density (76‐channel) EEG seizure recordings, by comparing DeepSIF estimates with surgical resection outcome and seizure onset zone (SOZ). These findings show that the trained DeepSIF model outperforms other methods in estimating the spatial and temporal information of origins of ictal activities. It achieves a high spatial specificity of 96% and a low spatial dispersion of 3.80 ± 5.74 mm when compared to the resection region. The source imaging results also demonstrate good coverage of SOZ, with an average distance of 10.89 ± 10.14 mm (from the SOZ to the reconstruction). These promising results suggest that DeepSIF has significant potential for advancing noninvasive imaging of the origins of ictal activities in patients with focal epilepsy, aiding management of intractable epilepsy.
Effectiveness of Vidian Neurectomy in Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review and Meta‐Analysis
Kim, Ji‐Sun , Stybayeva, Gulnaz , Hwang, Se Hwan , Hwang, Se Hwan , Stybayeya, Gulnaz

Mayo Clinic

Otolaryngology–Head and Neck Surgery | October 28, 2024 | Volume: 172 | Issue: 3 | Pages: 787-797

10.1002/ohn.1037 | PMID 39467055 Get It

AbstractObjectiveTo evaluate the clinical efficacy of vidian neurectomy (VN) or posterior nasal neurectomy (PNN) combined with endoscopic sinus surgery (ESS) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).Data SourcesA systematic search of six databases (PubMed, SCOPUS, Embase, Web of Science, Google Scholar, and Cochrane) was conducted to identify relevant studies up to May 2024.Review MethodsThe effects of combining VN or PNN with ESS were evaluated in comparison to ESS alone. Outcomes were assessed by evaluating changes in Lund‐Kennedy score, patient‐reported symptom scores (VAS), quality of life, as well as adverse effects and recurrence rate of CRSwNP.ResultsA total of 6 studies, comprising 407 patients, were included in the analysis. The neurectomy group showed significant improvements in Lund‐Kennedy score (SMD = 0.7276 [0.5695; 0.8857]), with statistically significant improvements maintained at 6, 12, and 24 months postoperatively. The treatment group maintained better improvements in sinusitis‐related quality of life (SMD = 0.4540 [0.1784; 0.7297]) and VAS (SMD = 0.7096 [0.4356; 0.9837]) until 12 months postoperatively, but not at 24 months. Regarding adverse effects, additional neurectomy did not significantly induce epistaxis (odds ratio [OR] = 0.9806 [0.2348; 4.0960]) or dry eye (OR = 2.4194 [0.1114; 52.5255]) compared to the control group. On the other hand, there was no difference in the recurrence rate of CRSwNP between the 2 groups during the follow‐up periods.ConclusionAdditional neurectomy shows better efficacy in improving endoscopic findings and symptoms in patients with CRSwNP and appears to be a safe and effective treatment.
FBF1 Deficiency Protects against Chronic Progression of Cisplatin-Induced AKI
Robichaud, Jielu Hao, Sun, Xiaobo , Hu, Jinghua , Hao, Jielu , Chen, Chuan , He, Kai , Dong, Zheng

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.2024hankv8re Get It

Comparative PKD1 and PKD2 Missense Variant Profiling Aids Molecular Diagnoses and Reveals Common Pathomechanisms and Variant Subtypes across the ADPKD Spectrum
Gainullin, Vladimir G. , Heyer, Christina M., Elbarougy, Doaa E. , Senum, Sarah R. , Sun, Xiaobo , Yang, Hana , Senum, Sarah R , Elbarougy, Doaa E , Sieben, Cynthia J. , Wang, Zhifei , Sturmlechner, Ines , Yu, Yong , Harris, Peter C.

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.202471vvcgzj Get It

S1931 The Utilization of Non-Invasive Tests (NITs) for the Clinical Management of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in the United States
Alkhouri, Naim , Nouredden, Mazen, Wong, Vincent Wai-Sun, Tsochatzis, Emmanuel , Deavila, Leyla, Racila, Andrei, Stepanova, Maria M. , Nader, Fatema, Lazarus, Jeffrey V. , Younossi, Zobair M. , Lazarus, Jeffrey V , Tsochatzis, Emmanuel A , Allen, Alina M. , Wong, Vincent Wai‐Sun , Mark, Henry E. , Castera, Laurent

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S1384-S1384

10.14309/01.ajg.0001037092.44862.28 Get It

Recent advances of nanomaterials in imaging liver fibrosis
Cui, Jin , Xu, Xueli , Ren, Ke , Dong, Mengzhen , Nie, Zhaokun, Xu, Yang , Dai, Xiaohui , Xu, Peng , Zhao, Xinya , Zhao, Xinya , Zhang, Shuxuan , Sun, Shuo , Sun, Xiao Jun

Mayo Clinic

BMEMat | October 16, 2024 | Volume: 3 | Issue: 2 | Pages: No page available

10.1002/bmm2.12123 Get It

AbstractLiver fibrosis is a pathological process resulting from prolonged exposure to various injury factors. It is characterized by the abnormal proliferation and activation of hepatic stellate cells and excessive deposition of extracellular matrix. If left untreated, it can progress to cirrhosis, liver failure, and even liver cancer. There is currently no efficient and accurate clinical diagnostic method for early liver fibrosis. Therefore, there is an urgent need to address the challenge of accurate staging and early diagnosis of liver fibrosis in clinical practice. Recently, nanomaterials have demonstrated significant potential for enhancing the diagnosis of liver fibrosis. Nanomaterials possess the ability to precisely identify and target the microenvironment associated with liver fibrosis. By enhancing their enrichment in the target area, nanomaterials can improve imaging contrast of fibrosis lesions in the liver, thereby enabling accurate diagnosis of liver fibrosis. Accordingly, this review delves into the latest research and advancements concerning nanomaterials in liver fibrosis diagnosis.